SAN DIEGO, Nov. 11, 2022 (GLOBE NEWSWIRE) —

The class: Robbins LLP Reminds investors that a shareholder is bringing a class action lawsuit alleging violations of filed the Securities Exchange Act of 1934. Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases.

What now: Shareholders in a similar situation may be eligible to participate in the class action lawsuit against Eiger Biopharmaceuticals, Inc. Shareholders who wish to be named lead plaintiff in the class action must file their filings by January 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in conducting the litigation. You do not have to be present at the case to be eligible for a recovery. Click for more information here.

All representations are on a contingency fee basis. Shareholders pay no fees or costs.

What is it about in this case: Eiger Biopharmaceuticals, Inc. has misled shareholders regarding the viability of its product candidate to treat COVID-19

According to the complaint, Eiger’s product candidates include peginterferon lambda, which is being evaluated for the treatment of COVID-19 in the TOGETHER study – a Phase 3 study evaluating multiple therapies in newly diagnosed, out-of-hospital, high-risk patients with mild to moderate COVID-19. In March 2022, based on the results of the TOGETHER study, Eiger announced that it had filed an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for peginterferon lambda to treat patients I am also submitting mild to moderate COVID-19 (the “Peginterferon Lambda EUA”).

During class time, the defendants failed to disclose that the defendants overstated Eiger’s clinical and regulatory drug…